The global market for cardiac surgery and heart valve devices includes tissue heart valves, mechanical heart valves, annuloplasty repair devices, transcatheter mitral valve repair (TMVr) devices, transcatheter aortic heart valve implantation (TAVI) devices, on-pump coronary artery bypass (ONCAB) devices, off-pump coronary artery bypass (OPCAB) devices, autotransfusion (AD) devices, endoscopic vessel harvesting (EVH) devices, anastomosis assist devices (AADs), ventricular assist devices (VADs), intra-aortic balloon pump (IABP) devices, patent foramen ovale (PFO) devices, atrial and ventricular septal defect (ASD and VSD) devices, left atrial appendage closure (LAA) devices, preshaped guidewires and cerebral embolic protection devices.

The global Heart Defects Closure Device Market Reportcontains analysis for Patent Foramen Ovale Closure Devices and Atrial & Ventricular Septal Defect Closure Devices. The global patent foramen ovale closure market and global atrial & ventricular septal defect closure markets are expected to reach $322.7M and $226.2M by 2027, respectively.

Atrial fibrillation (AF) is an abnormal heart rhythm. Patients with AF experience episodes of rapid and irregular beating. As a result of the irregular beating, the atrium in AF patients does not completely contract, impeding the flow of blood from the atria into the ventricles. Blood that is not expelled from the left atria collects in the sac-shaped LAA. Once in the LAA, the movement of the blood slows.

Off-pump coronary artery bypass (OPCAB), or simply beating-heart coronary artery bypass grafting, uses a median sternotomy to access the heart, similar to on-pump coronary artery bypass (ONCAB) procedures. The important difference is that the cardiopulmonary bypass pump is not employed. Clinical studies show that OPCAB offers several benefits compared to ONCAB procedures, including reductions in bleeding, short-term neurocognitive dysfunction, kidney dysfunction and length of hospital stay.

Surgical heart valve replacement procedures can be performed using tissue or mechanical heart valves. Tissue valve procedures can be classified by valve replaced (aortic, mitral, tricuspid or pulmonary), by material (xenograft or allograft) or device type (stented, sutureless or stentless). Mechanical valves can be classified by valve replaced (aortic, mitral, tricuspid or pulmonary) or by conduit (with conduit or without conduit).

Of the four valves in the human heart (mitral valve, tricuspid valve, aortic valve and pulmonary valve), the mitral valve is most prone to regurgitation. This is a condition where blood is funneled back into the left atrium of the heart. Mitral regurgitation (MR) can either be caused by a congenital defect or myxomatous degeneration of the valve.

Ventricular assist devices (VADs) are used to aid a failing heart by supplementing the pumping function of the heart. VADs are often used in patients with advanced heart failure (HF). HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pump power of the heart, which causes the heart to become too weak to pump blood at a level sufficient to meet the body’s demands.

Global TAVI/TAVR, CEPD, and Pre-Shaped Guidewire markets are expected to increase to reach $8.4 billion, $492.3 million, and $70.9 million. The analysis includes in-depth procedure numbers, which will seemingly increase over the forecast period, along with the impact of COVID-19 on the procedure volume.

Globally, over 6 million cardiac surgery procedures were performed in 2020. The majority of these procedures were autotransfusion procedures followed by surgical heart valve procedures. Over the forecast period, all of the procedures included in this report are projected to experience growth, some faster than others, following COVID-19 headwinds. 

In 2020, the U.S. cardiac surgery market size was valued at $7.2 billion, with over 91,000 transcatheter heart valve replacement (TAVR) procedures performed every year. The market size is expected to increase at a growth rate of 7.7% to reach $12.1 billion in 2026. Throughout this medical market research, we analyzed 43 cardiac surgery companies

In 2020, the European cardiac surgery device market size was valued at €2.6 billion, with over 50,000 Transcatheter Aortic Valve Implantation (TAVI) procedures performed. Despite COVID19, the market size is expected to reach an insane €5.6 billion in 2026. Throughout this medical market research, we analyzed 40 cardiac surgery companies across 15 countries in Europe